Puma Liabilities And Stockholders Equity from 2010 to 2026
| PBYI Stock | USD 6.22 0.17 2.81% |
Liabilities And Stockholders Equity | First Reported 2007-09-30 | Previous Quarter 202.9 M | Current Value 217.7 M | Quarterly Volatility 100.6 M |
Review Puma Biotechnology financial statements over time to add context on performance and capital structure. Key drivers include Interest Expense of 5.8 M, Other Operating Expenses of 181.4 M or Operating Income of 39.2 M along with ratios such as Price To Sales Ratio of 1.37, Dividend Yield of 0.0 or PTB Ratio of 2.17. This view complements Puma Biotechnology Valuation and Volatility modules.
Puma | Liabilities And Stockholders Equity | Build AI portfolio with Puma Stock |
The Liabilities And Stockholders Equity trend for Puma Biotechnology offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Puma Biotechnology is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Puma Biotechnology's Liabilities And Stockholders Equity Growth Pattern
Below is the plot of the Liabilities And Stockholders Equity of Puma Biotechnology over the last few years. It is the total of all liabilities and equity in the company, which should equal the company's total assets according to the accounting equation. Puma Biotechnology's Liabilities And Stockholders Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Puma Biotechnology's overall financial position and show how it may be relating to other accounts over time.
| Liabilities And Stockholders Equity | 10 Years Trend |
|
Liabilities And Stockholders Equity |
| Timeline |
Puma Liabilities And Stockholders Equity Regression Statistics
| Arithmetic Mean | 185,489,852 | |
| Geometric Mean | 139,201,155 | |
| Coefficient Of Variation | 39.34 | |
| Mean Deviation | 57,030,174 | |
| Median | 216,302,000 | |
| Standard Deviation | 72,967,672 | |
| Sample Variance | 5324.3T | |
| Range | 257.7M | |
| R-Value | 0.64 | |
| Mean Square Error | 3386.1T | |
| R-Squared | 0.40 | |
| Significance | 0.01 | |
| Slope | 9,181,856 | |
| Total Sum of Squares | 85188.5T |
Puma Liabilities And Stockholders Equity History
Puma Biotechnology Fair Value and Market Price
Puma Biotechnology is a small-cap equity in Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care categories. Valuation integrates earnings durability and capital efficiency. Market-sensitive characteristics amplify cycle exposure. We evaluate Puma Biotechnology through the lens of long-term portfolio construction and diversification efficiency.
Methodology
Unless otherwise specified, financial data for Puma Biotechnology is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Puma (USA Stocks:PBYI) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions Valuation estimates and intrinsic-value models use inputs from public financial disclosures and may not represent market consensus.
Assumptions
Our reporting uses public filings and market reference sources and institutional disclosures from U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Normalization procedures may introduce minor timing offsets. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.Analyst Sources
Puma Biotechnology is covered by 1 analyst. Representative analyst firms may include Bernstein Research, Deutsche Bank, Morgan Stanley, BMO Capital Markets, Guggenheim Securities, among others. Updates may occur throughout the day.
Currently Active Assets on Macroaxis
More Resources for Puma Stock Analysis
A structured review of Puma Biotechnology often starts with core financial statements and trend context. Key ratios help frame profitability, efficiency, and growth context for Puma Biotechnology Stock. Outlined below are key reports that provide context for Puma Biotechnology Stock:Review Puma Biotechnology Correlation against competitors for Puma Biotechnology. This adds peer-relative context. For information on how to trade Puma Stock refer to our How to Trade Puma Stock guide.Analysis related to Puma Biotechnology should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Quarterly Earnings Growth -0.34 | Earnings Share 0.61 | Revenue Per Share | Quarterly Revenue Growth 0.277 | Return On Assets |
The market value of Puma Biotechnology is measured differently than book value, which reflects Puma accounting equity. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Market price can move with sentiment, cycles, and liquidity conditions, so it may drift away from fundamentals. Valuation methods compare these perspectives to frame context.
Note that Puma Biotechnology's intrinsic value and market price are different measures derived from different inputs. Analysis often considers earnings, revenue quality, fundamentals, technical signals, competition, and analyst coverage. By contrast, market price reflects the level where buyers and sellers transact.